Chronic myeloid leukemia patients

BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients... 

Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. Several types of mutations of the ABL gene ean be found in chronic myeloid leukemia patients resistant to STI571, and they ean pre-exist to the onset of treatment. B/oor/2002 100 1014-1018. 

Frank O, Brors B, Fabarius A et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006 20 1400-1407. 

Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004 50 1205-1213. Jaeobberger JW, Sramkoski RM, Frisa PS et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a eell-based measure of BCR-ABL kinase activity. Cytometry A 2003 54 75-88. 

As representative of the derivatives of pyridoacridine, eilatin, a marine alkaloid inhibits in vitro cell proliferation in chronic myeloid leukemia patients [244], Other members of the pyridoacridines, such as alkaloids isolated from a Cystodytes sp. ascidian, inhibit topoisomerase II [245], Additionally, analogues derivatives of these type of alkaloids showed interesting anti-HIV activity [246],... 

Peng B et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 935-942... 

B. Peng, M. Hayes, D. Resta,A. Racine-Poon, B. J. Druker, M.Talpaz, C. L. Sawyers, M. Rosamilia, J. Ford, P. Lloyd, and R. Capdeville, Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients, J. Clin. Oncol. 22 (2004), 935-942. 

Rapid exacerbation (1-21 days) or delayed (3-38 months) de novo appearance of immune hemolytic anemia has been reported after initiation of interferon alfa treatment in nine patients with lymphoproliferative disorders (220). However, this rare event was identified in only 1% of 581 patients receiving interferon alfa alone or as part of a chemotherapeutic regimen for chronic myelogenous leukemia (221). A mechanism close to that observed with alpha-methyldopa has been thought to be involved (208). The direct antiglobulin test was positive in 32% of 28 chronic myeloid leukemia patients after a median of 1 year of treatment with interferon alfa (222). 

Steegmann JL, Pinilla I, Requena MJ, de la Camara R, Granados E, Fernandez ViUalta MJ, Fernandez-Ranada JM. The direct antiglobulin test is frequently positive in chronic myeloid leukemia patients treated with interferon-alpha. Transfusion 1997 37(4) 446-7. 

Kozuch P, Talpaz M, Faded S, O Brien S, Freireich EJ, Kantarjian H. Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha a synergistic correlation Cancer 2000 89(7) 1482-9. 

Lin F, van Rhee F, Goldman JM, et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996 7 4473-78. 

Jorgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., Smith, K. D, 2002, a 1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI57 Blood. 99, 713-715. Jullien, M., Garel, J-R., Merola, F. and Brochon J-C, 1986, Quenching by acrylamide and temperature of a fluorescent probe attached to the active site of ribonuclease. European Biophysical Journal 13, 131-137... 

Elias MH, Baba AA, Husin A, Sulong S, Hassan R, Sim GA, Wahid SEA, Ankathil R. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int 2012 2013 129715. doi 10.1155/2013/129715. 

The Philadelphia translocation t(9 22) (q34 qll) or Philadelphia chromosome is a chromosomal defect resulting in gene fusion of the BCR and ABL genes. The resultant fusion gene is the BCR-ABL oncogene. The Philadelphia chromosome is a cytogenetic abnormality seen in 95 % of chronic myeloid leukemia patients and 15-30 % of adults with acute lymphoblastic leukemia. 

---